Eptifibatide

Name: Eptifibatide
Brand: MedChemExpress
SKU: HY-B0686
Rating: 5.0 (9 reviews)

Cat. No.: HY-B0686 Purity: 99.79%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 188627-80-7

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Eptifibatide:

Eptifibatide acetate In-stock
Eptifibatide monoacetate Get quote

9 Publications Citing Use of MCE Eptifibatide

Bio/Physico-chemical Assay

Histological Imaging/Staining

In Vivo Efficacy Study

: Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]; The median fluorescence intensity of HRG and platelets were calculated and plotted over time from mice treated or untreated with Eptifibatide (10 μg/g body weight, repeated every 15-20 min).

: Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]; The scatter plot of pixel intensities of green (HRG) and red (CD31) fluorescence in ROI1 and ROI2 as indicated were presented. The Pearson's correlation coefficients (r) for pixels with intensity above the threshold (indicated by the dashed lines) in the thrombus (ROI2) and in the area without the thrombus (ROI1-ROI2) were inserted. Veh vehicle, Epti eptifibatide.

: Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]; When mice were treated with eptifibatide, an integrin α_IIbβ3 antagonist that eliminated platelet deposition and thus platelet-derived Zn²⁺, HRG accumulation at the site of vessel injury was significantly reduced by 58.3%.

: Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.; Concentration eptifibatide in function of buffer volume eluted from the column.

: Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.; Calibration curve eptifibatide (0.25 mg/mL-0,00012207 mg/mL).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Integrin Isoform Specific Products:

View All Isoforms

αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
Platelet	IC₅₀	0.012 μM Compound: Eptifibatide	Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation	[PMID: 24461295]

In Vitro

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

831.96

Formula

C₃₅H₄₉N₁₁O₉S₂

CAS No.

188627-80-7

Appearance

Solid

Color

White to off-white

Sequence

MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2

Sequence Shortening

MPA-HAR-GDWPC-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (240.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (60.10 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2020 mL	6.0099 mL	12.0198 mL
5 mM	0.2404 mL	1.2020 mL	2.4040 mL
10 mM	0.1202 mL	0.6010 mL	1.2020 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (120.20 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.79%

Select Batch:

Data Sheet (274 KB) SDS (420 KB)

COA (250 KB) LCMS (88 KB)

Handling Instructions (2659 KB)

References

[1]. Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.2020 mL	6.0099 mL	12.0198 mL	30.0495 mL
	5 mM	0.2404 mL	1.2020 mL	2.4040 mL	6.0099 mL
	10 mM	0.1202 mL	0.6010 mL	1.2020 mL	3.0050 mL
	15 mM	0.0801 mL	0.4007 mL	0.8013 mL	2.0033 mL
	20 mM	0.0601 mL	0.3005 mL	0.6010 mL	1.5025 mL
	25 mM	0.0481 mL	0.2404 mL	0.4808 mL	1.2020 mL
	30 mM	0.0401 mL	0.2003 mL	0.4007 mL	1.0017 mL
	40 mM	0.0300 mL	0.1502 mL	0.3005 mL	0.7512 mL
	50 mM	0.0240 mL	0.1202 mL	0.2404 mL	0.6010 mL
	60 mM	0.0200 mL	0.1002 mL	0.2003 mL	0.5008 mL
DMSO	80 mM	0.0150 mL	0.0751 mL	0.1502 mL	0.3756 mL
DMSO	100 mM	0.0120 mL	0.0601 mL	0.1202 mL	0.3005 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Eptifibatide Related Classifications

Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Eptifibatide188627-80-7IntegrinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Eptifibatide

Customer Review

Other Forms of Eptifibatide:

Eptifibatide Related Antibodies

9 Publications Citing Use of MCE Eptifibatide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Integrin Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Eptifibatide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Eptifibatide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report